Our latest news
What We’re Working On
Media Contact
Katie Engleman
katie@1abmedia.com
Bringing Meaningful Therapies from One to Many
-
September 10th, 2025
Actio Biosciences to Participate in TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
Read More -
July 30th, 2025
Actio Biosciences Announces U.S. FDA Clearance of Investigational New Drug Application and Fast Track Designation for ABS-1230, a KCNT1 Inhibitor for the Treatment of KCNT1-Related Epilepsy
Read More -
July 7th, 2025
Actio Biosciences to Participate in Evercore Emerging Private Biotech Conference
Read More -
June 18th, 2025
Actio Biosciences Secures $66 Million Series B Financing to Advance Genetics-Driven Pipeline of Small Molecule Therapeutics for Rare and Common Diseases
Read More -
April 9th, 2025
Actio Biosciences to Participate in Piper Sandler Spring Biopharma Symposium
Read More